day 5 uterine transfer for Infertility

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Infertility
day 5 uterine transfer - Procedure
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

This trial is testing whether it's better to transfer embryos on day 3 or day 5 of IVF in patients with 5 or fewer embryos. The goal is to find the best way to maximize the chances of success for these patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 2 years

14 days
Clinical pregnancy
2 years
Time to pregnancy/live birth
9 months
Multiple pregnancy
Ongoing pregnancy
live birth

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

day 5 embryo transfer
1 of 2
day 3 embryo transfer
1 of 2
Experimental Treatment

658 Total Participants · 2 Treatment Groups

Primary Treatment: day 5 uterine transfer · No Placebo Group · N/A

day 5 embryo transfer
Procedure
Experimental Group · 1 Intervention: day 5 uterine transfer · Intervention Types: Procedure
day 3 embryo transfer
Procedure
Experimental Group · 1 Intervention: day 3 uterine transfer · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Boston IVFOTHER
17 Previous Clinical Trials
18,974 Total Patients Enrolled
16 Trials studying Infertility
18,674 Patients Enrolled for Infertility
Beth Israel Deaconess Medical CenterLead Sponsor
772 Previous Clinical Trials
847,895 Total Patients Enrolled
Werner Neuhausser, MD PhDPrincipal Investigator - Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center

Eligibility Criteria

Age 18 - 65 · Female Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have given your written, informed consent to participate in this study.
You have undergone an autologous IVF cycle.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: October 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Texas14.3%
Ohio14.3%
Florida10.7%
Other60.7%
How old are they?
18 - 65100.0%
What site did they apply to?
Boston IVF100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References